Hematology

Latest News

AML cells concept | image credit: sovova - stock.adobe.com
Study Reveals Leukemia Transplant Successes and Persistent Relapse Risks

November 21st 2024

Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.

Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

November 19th 2024

Don M. Benson, MD, PhD, James Cancer Hospital
Elevating Myeloma Care Amidst Complex Treatment Choices

November 15th 2024

Genes - CrazyJuke - stock.adobe.com
NUP98 Rearrangements Linked to Poor Outcomes in AML

November 15th 2024

Tacrolimus | Image Credit: © MQ-Illustrations - stock.adobe.com
Tacrolimus Linked to Lower Acute GVHD Risk

November 7th 2024

More News

Optimizing Frontline Therapy in Multiple Myeloma
July 25th 2018

Optimizing Frontline Therapy in Multiple Myeloma

Daratumumab's Potential as Frontline Therapy for MM
July 25th 2018

Daratumumab's Potential as Frontline Therapy for MM

Frontline Treatment Options for Multiple Myeloma
July 25th 2018

Frontline Treatment Options for Multiple Myeloma

Considerations for Newly Diagnosed Multiple Myeloma
July 25th 2018

Considerations for Newly Diagnosed Multiple Myeloma

Increasingly Improved Outcomes for Multiple Myeloma
July 25th 2018

Increasingly Improved Outcomes for Multiple Myeloma

Treating Multiple Myeloma Through Multiple Relapses
July 25th 2018

Treating Multiple Myeloma Through Multiple Relapses

Incremental Changes in Therapy at MM Relapse
July 25th 2018

Incremental Changes in Therapy at MM Relapse

Multiple Myeloma: Approaching Treatment at First Relapse
July 25th 2018

Multiple Myeloma: Approaching Treatment at First Relapse

Optimizing Treatment for MM: Transplant and Maintenance
July 25th 2018

Optimizing Treatment for MM: Transplant and Maintenance

Newly Diagnosed Multiple Myeloma: Frontline Options
July 25th 2018

Newly Diagnosed Multiple Myeloma: Frontline Options

Selecting Therapy for Newly Diagnosed Myeloma
July 25th 2018

Selecting Therapy for Newly Diagnosed Myeloma

Combination Therapy: Improving Multiple Myeloma Outcomes
July 25th 2018

Combination Therapy: Improving Multiple Myeloma Outcomes

Second Biosimilar Approved to Treat Neutropenia
July 25th 2018

Second Biosimilar Approved to Treat Neutropenia

Laura Joszt, MA
A second biosimilar to Amgen’s Neupogen, which treats neutropenia, has been approved in the United States. The FDA approved Pfizer’s filgrastim-aafi, which will be sold under the brand name Nivestym. Zarxio (filgrastim-sndz) was the first filgrastim biosimilar approved by the FDA in 2015.
First Targeted Therapy Approved for R/R AML With IDH1 Mutation
July 22nd 2018

First Targeted Therapy Approved for R/R AML With IDH1 Mutation

Laura Joszt, MA
The FDA approved the first targeted therapy for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. In addition, FDA also approved a companion diagnostic to be used to detect the specific mutations in the IDH1 gene.
Quizartinib Effective in Patients With FLT3-ITD–Positive Relapsed, Refractory AML
July 17th 2018

Quizartinib Effective in Patients With FLT3-ITD–Positive Relapsed, Refractory AML

David Bai
A phase 2 trial evaluated the safety and efficacy of quizartinib in patients with relapsed/refractory acute myeloid leukemia (AML), compared with salvage chemotherapy.
Screening Tool Could Predict Risk of Developing AML Years Before Disease Onset
July 16th 2018

Screening Tool Could Predict Risk of Developing AML Years Before Disease Onset

Laura Joszt, MA
Acute myeloid leukemia can often appear suddenly in patients, without any detectable early symptoms. However, new research has identified the origins of AML, which can be detectable more than 5 years before the disease develops.
Characteristics of Patients With CML Willing to Attempt Treatment-Free Remission
July 12th 2018

Characteristics of Patients With CML Willing to Attempt Treatment-Free Remission

Laura Joszt, MA
Only 34% of patients with chronic myeloid leukemia (CML) in a small study in China were likely to be positive about attempting treatment-free remission.
CLL: Combination Strategies and Unmet Needs
July 11th 2018

CLL: Combination Strategies and Unmet Needs

CLL: Rationale for Ibrutinib and Sequencing
July 11th 2018

CLL: Rationale for Ibrutinib and Sequencing

Initiating Frontline Therapy in CLL
July 11th 2018

Initiating Frontline Therapy in CLL

The Biology and Diagnosis of CLL
July 11th 2018

The Biology and Diagnosis of CLL

Combination Therapy Values and Future Outlook in CLL
July 11th 2018

Combination Therapy Values and Future Outlook in CLL

CLL: Impact of Combination Therapies on Managed Care
July 11th 2018

CLL: Impact of Combination Therapies on Managed Care

Role of Real-World Data and Sequencing in CLL
July 11th 2018

Role of Real-World Data and Sequencing in CLL

CLL: Treatment Pathway Changes and Cost Effectiveness
July 11th 2018

CLL: Treatment Pathway Changes and Cost Effectiveness

Clinical Impact of the RESONATE-2 Trial in CLL
July 11th 2018

Clinical Impact of the RESONATE-2 Trial in CLL

CLL: Managed Care Outlook on Clinical Trial Data
July 11th 2018

CLL: Managed Care Outlook on Clinical Trial Data

Coverage and Clinical Support in CLL Treatment
July 11th 2018

Coverage and Clinical Support in CLL Treatment

Diagnostic Factors and Treatment Changes in CLL
July 11th 2018

Diagnostic Factors and Treatment Changes in CLL

CLL: Addressing Treatment Paradigms and Unmet Needs
July 11th 2018

CLL: Addressing Treatment Paradigms and Unmet Needs

<1
...
121314151617181920
...
23>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo